How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?

Overview

Journal J Atheroscler Thromb

Date 2022 Jan 13

PMID 35022364

Authors

Yu Kataoka

Sayaka Funabashi

Takahito Doi

Mariko Harada-Shiba

Affiliations

Soon will be listed here.

Abstract

Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder that elevates low-density lipoprotein cholesterol and increases the risk of premature atherosclerotic cardiovascular disease (ASCVD). However, despite their atherogenic lipid profiles, the cardiovascular risk of HeFH varies in each individual. Their variety of phenotypic features suggests the need for better risk stratification to optimize their therapeutic management. The current review summarizes three potential approaches, including (1) definition of familial hypercholesterolemia (FH)-related risk scores, (2) genetic analysis, and (3) biomarkers. The International Atherosclerosis Society has recently proposed a definition of severe FH to identify very high-risk HeFH subjects according to their clinical characteristics. Furthermore, published studies have shown the association of FH-related genetic phenotypes with ASCVD, which indicates the genetic analysis's potential to evaluate individual cardiovascular risks. Biomarkers reflecting disease activity have been considered to predict the formation of atherosclerosis and the occurrence of ASCVD in HeFH subjects. Incorporating these risk stratifications will be expected to allocate adequate intensity of lipid-lowering therapies in HeFH subjects, which ultimately improves cardiovascular outcomes.

Citing Articles

Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia.

Tada H, Kawashiri M, Nohara A, Sekiya T, Watanabe A, Takamura M Genes (Basel). 2024; 15(3).

PMID: 38540356 PMC: 10970256. DOI: 10.3390/genes15030297.

Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.

Rakocevic J, Dobric M, Vucic R, Furtula M, Zaletel I, Milutinovic K Int J Mol Sci. 2023; 24(6).

PMID: 36983086 PMC: 10056056. DOI: 10.3390/ijms24066012.

References

Kataoka Y, Harada-Shiba M, Nakao K, Nakashima T, Kawakami S, Fujino M . Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017; 11(2):413-421.e3. DOI: 10.1016/j.jacl.2017.01.005. View

Hopkins P, Toth P, Ballantyne C, Rader D . Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5(3 Suppl):S9-17. DOI: 10.1016/j.jacl.2011.03.452. View

Paquette M, Bernard S, Cariou B, Hegele R, Genest J, Trinder M . Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2021; 41(10):2632-2640. DOI: 10.1161/ATVBAHA.121.316106. View

Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps O . Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45):3478-90a. PMC: 3844152. DOI: 10.1093/eurheartj/eht273. View

Naito R, Daida H, Masuda D, Harada-Shiba M, Arai H, Bujo H . Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. J Atheroscler Thromb. 2021; 29(8):1188-1200. PMC: 9371754. DOI: 10.5551/jat.63019. View

Perez-Calahorra S, Sanchez-Hernandez R, Plana N, Marco-Benedi V, Pedro-Botet J, Almagro F . Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients. Am J Cardiol. 2017; 119(5):742-748. DOI: 10.1016/j.amjcard.2016.11.025. View

Conroy R, Pyorala K, Fitzgerald A, Sans S, Menotti A, De Backer G . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24(11):987-1003. DOI: 10.1016/s0195-668x(03)00114-3. View

de Isla L, Watts G, Alonso R, Diaz-Diaz J, Muniz-Grijalvo O, Zambon D . Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. Eur Heart J. 2021; 42(22):2201-2211. DOI: 10.1093/eurheartj/ehaa1066. View

Khera A, Won H, Peloso G, Lawson K, Bartz T, Deng X . Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol. 2016; 67(22):2578-89. PMC: 5405769. DOI: 10.1016/j.jacc.2016.03.520. View

10.

Gidding S, Champagne M, de Ferranti S, Defesche J, Ito M, Knowles J . The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015; 132(22):2167-92. DOI: 10.1161/CIR.0000000000000297. View

11.

Sjouke B, Defesche J, Hartgers M, Wiegman A, Roeters van Lennep J, Kastelein J . Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease. J Clin Lipidol. 2016; 10(6):1462-1469. DOI: 10.1016/j.jacl.2016.09.003. View

12.

Humphries S, Cooper J, Capps N, Durrington P, Jones B, McDowell I . Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register. Atherosclerosis. 2018; 281:207-212. PMC: 6403443. DOI: 10.1016/j.atherosclerosis.2018.11.014. View

13.

Sniderman A, Tsimikas S, Fazio S . The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014; 63(19):1935-47. DOI: 10.1016/j.jacc.2014.01.060. View

14.

van Wissen S, Trip M, Smilde T, de Graaf J, Stalenhoef A, Kastelein J . Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis. 2002; 165(2):361-6. DOI: 10.1016/s0021-9150(02)00280-0. View

15.

Nordestgaard B, Chapman M, Ray K, Boren J, Andreotti F, Watts G . Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23):2844-53. PMC: 3295201. DOI: 10.1093/eurheartj/ehq386. View

16.

Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers J, Boileau C . In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem. 2010; 286(6):4257-63. PMC: 3039354. DOI: 10.1074/jbc.M110.192104. View

17.

Iadecola C, Parikh N . Framingham General Cardiovascular Risk Score and Cognitive Impairment: The Power of Foresight. J Am Coll Cardiol. 2020; 75(20):2535-2537. PMC: 7853244. DOI: 10.1016/j.jacc.2020.03.061. View

18.

Tsimikas S . A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017; 69(6):692-711. DOI: 10.1016/j.jacc.2016.11.042. View

19.

Tada H, Hori M, Matsuki K, Ogura M, Nohara A, Kawashiri M . Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene. J Atheroscler Thromb. 2021; 29(6):816-824. PMC: 9174093. DOI: 10.5551/jat.62869. View

20.

Kataoka Y, Harada-Shiba M, Hori M, Watanabe M, Kokubo Y, Noguchi T . Circulating Furin-Cleaved Proprotein Convertase Subtilisin/Kexin Type 9 Concentration Predicts Future Coronary Events in Japanese Subjects. JACC Asia. 2022; 1(3):360-368. PMC: 9627806. DOI: 10.1016/j.jacasi.2021.09.003. View